چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| Acute Myeloid Leukemia (AML) is a malignant hematopoietic disease caused by the presence of a malignant clone in the bone marrow. The classic AML treatment includes a combination of an Anthracycline and Cytarabine. This study aimed to evaluate the effect of high doses of Daunorubicin on patients' outcome. Methods: During the study period, 16 AML patients received induction therapy with Cytarabine (100 mg/m2/d) for 7 days and Daunorubicin (90 mg/m2/d) for 3 days. Outcome analysis was performed to evaluate the overall survival (OS) and disease-free survival (DFS) during 2 years of study. Results: The mean age of patients was 38 ± 12.38 years, with the age range between 16 and 54 years old. Seven patients (43.8%) were females, and 9 cases (56.3%) were males. OS was 81.3%, with a mean of 396.88 days. (95% CI: 306.99-486.77). DFS was 83.3%, with a mean of 383.57 days (95% CI: 299.88-467.26). The log-rank test showed a signifcant difference in DFS of AML sub-types, as M1 subtypes had lower DFS (P log-rank= 0.013). Although M1 subtypes had a lower OS, there was no signifcant difference in OS between subgroups (P log-rank= 0.067). Conclusion: Although disease-free survival was improved by increasing the dose of daunorubicin, there was no difference in the overall survival between the AML subgroups and sexes. |
| نویسنده | نفر چندم مقاله |
|---|---|
| رویا دولت خواه | اول |
| علیرضا نیکانفر | سوم |
| علی اصفهانی | چهارم |
| سید هادی چاوشی | پنجم |
| بابک نجاتی | ششم |
| زهره صناعت | هفتم |
| عفت ایرانی جم | دوم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| Outcome analysis of acute myeloid leukemia patients.pdf | 1398/06/26 | 1215213 | دانلود |
